FDA accepts Roche ’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer
Roche announced today that the U.S. Food and Drug Administration (FDA) has accepted the company ' s supplemental Biologics License Application (sBLA) for Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Ovarian Cancer | Ovaries | Pharmaceuticals | Women